IRIS
SCARFO', LYDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 437
EU - Europa 432
AS - Asia 37
OC - Oceania 2
Totale 908
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 435
SE - Svezia 315
IT - Italia 54
CN - Cina 24
IE - Irlanda 17
DE - Germania 15
FI - Finlandia 11
NL - Olanda 7
AE - Emirati Arabi Uniti 6
PL - Polonia 4
IN - India 3
NO - Norvegia 3
AU - Australia 2
CA - Canada 2
ES - Italia 2
FR - Francia 2
DK - Danimarca 1
IL - Israele 1
IR - Iran 1
PH - Filippine 1
RU - Federazione Russa 1
SG - Singapore 1
Totale 908
Salva come PNG Salva come JPEG
Città #
Ashburn 98
Lawrence 96
Princeton 96
New York 56
Milan 31
Shanghai 21
Dublin 17
Helsinki 11
Dubai 6
Rome 5
Meppel 4
Warsaw 4
Los Angeles 3
Pune 3
Barcelona 2
Bergen 2
Frankfurt am Main 2
Melbourne 2
Mountain View 2
Padova 2
Paris 2
San Maurizio d'Opaglio 2
Alessandria 1
Anzio 1
Easley 1
Esslingen am Neckar 1
Fremont 1
Groningen 1
Hangzhou 1
Ismaning 1
Lomazzo 1
Lonate Pozzolo 1
Nauka 1
Novara 1
Oslo 1
Quezon City 1
Redmond 1
Redwood City 1
Rockville 1
Sarcedo 1
Toronto 1
Verona 1
Washington 1
Zanjan 1
Totale 489
Salva come PNG Salva come JPEG
Nome #
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 18
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 18
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 18
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 18
Prognostic relevance of MYD88 mutations in CLL: the jury is still out 16
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 16
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 16
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 15
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 15
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 15
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia 15
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 15
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 15
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities 15
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia 14
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 14
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia 14
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 14
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 14
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 13
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 13
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 13
Targeting B-cell anergy in chronic lymphocytic leukemia. 13
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 13
3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells 13
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 12
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 12
Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Time to Retire? 12
MBL Versus CLL How Important Is the Distinction? 11
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 11
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 11
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 11
Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL) 11
Infrequent "chronic lymphocytic leukemia-specific" immunoglobulin stereotypes in aged individuals with or without low count monoclonal B cell lymphocytosis 11
Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients 11
Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia 11
Relevance of Minimal Residual Disease in the Era of Targeted Agents 11
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 11
Toll-Like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation 11
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 10
Monoclonal B lymphocytosis in the general population 10
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 10
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL 10
Chronic lymphocytic leukaemia 10
Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia 10
The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia 10
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia 10
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 10
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 10
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment 10
The evolving treatment landscape of chronic lymphocytic leukemia 10
Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia 10
High-throughput analysis of the T-cell receptor gene repertoire in low-count monoclonal B-cell lymphocytosis reveals a distinct profile from chronic lymphocytic leukemia 10
Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line 10
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 10
CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? 9
Monoclonal B cell lymphocytosis and "in situ" lymphoma 9
Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines? 9
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations 9
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. 9
What does it mean i have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges 9
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors 9
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation 9
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 9
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 9
Single cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib 9
Profiling the Genomic Landscape at the Early Stages of CLL: Low Genomic Complexity and Paucity of Driver Mutations in MBL and Indolent CLL 9
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 9
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia 8
Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression 8
IgG-Switched CLL Has a Distinct Immunogenetic Signature from the Common MD Variant: Ontogenetic Implications 8
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy 8
Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia 8
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies 8
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 8
Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography 8
Monoclonal B Cell Lymphocytosis in Hepatitis C Virus Infected Individuals 7
Highly similar genomic landscapes in monoclonal b-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations 7
Recurrent mutations refine prognosis in chronic lymphocytic leukemia 7
MyPal ADULT study protocol: A randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies 7
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 7
MyPal-Child study protocol: An observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients 7
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 7
The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors 6
Histopathological EXAMINATION of BONE MARROW Biopsy (BMB) IN Primary Splenic B CELL Lymphomas of Marginal-ZONE ORIGIN (PSMZL). A Reliable Substitute for Spleen Pathology? 6
Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia 6
Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line 6
High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): The HD-K phase II trial 6
Disordini plasmacellulari 6
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study 6
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 5
Toll-like receptor 9 stimulation can induce I kappa B zeta expression and IgM secretion in chronic lymphocytic leukemia cells 5
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 5
Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control 5
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era 5
Six Months Antibody Persistence after BNT162b2 mRNA COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukemia 5
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia 5
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy 5
Monoclonal B-cell lymphocytosis: Does the elderly patient need a specialistic approach? 4
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial 4
Totale 1.010
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.567
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.567
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201 1 0 0 0 0 0 0 0 0 0 0 0
2020/202140 0 0 0 0 31 5 4 0 0 0 0 0
2021/202271 0 0 0 21 6 3 8 19 6 5 2 1
2022/2023572 213 111 53 1 14 80 21 31 39 0 9 0
2023/2024280 7 19 26 108 21 68 3 20 0 6 2 0
Totale 1.017